Loading
A phase 2/3 trial of Izalontamab brengitecan, Osimertinib, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) is a phase 2/3 interventional study registered as NCT07642024 by Sichuan Baili Pharmaceutical Co., Ltd., with 90 participants planned, started 2026-07-24 and due to reach its primary completion in 2032-12. Interventions recorded: BL-B01D1, Osimertinib, Carboplatin, Pemetrexed, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Izalontamab brengitecan, Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer.